产品
编 号：F745283
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1447814-75-6
产品详情
生物活性：
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.
体内研究：
Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft.Brontictuzumab (20 mg/kg, i.p., every 4?days) inhibits DLL4 induced activation of Notch1 in MCL model.Animal Model:T-ALL xenograft
Dosage:15 mg/kg
Administration:Intraperitoneal injection (i.p.), twice weekly.
Result:Inhibited tumor growth and reduced the size of the spleen.Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.
Animal Model:NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo
Dosage:20 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth.
体外研究：
Brontictuzumab (0-100 μg/mL) inhibits Notch1 signaling, including DLL4, JAG1/2 activity.Brontictuzumab (25 μg/mL, 4 days) reduces the levels of Notch1 intracellular domain in the HPB-ALL cell line.Brontictuzumab (25 μg/mL, 48 h) inhibits DLL4-mediated cleaved-Notch1 overexpression in MCL cells.Brontictuzumab (25 μg/mL, 48 h) blocks the increased phosphorylation of both, MEK and ERK by DLL4 stimulation in Mino cells.
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.
体内研究：
Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft.Brontictuzumab (20 mg/kg, i.p., every 4?days) inhibits DLL4 induced activation of Notch1 in MCL model.Animal Model:T-ALL xenograft
Dosage:15 mg/kg
Administration:Intraperitoneal injection (i.p.), twice weekly.
Result:Inhibited tumor growth and reduced the size of the spleen.Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.
Animal Model:NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo
Dosage:20 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth.
体外研究：
Brontictuzumab (0-100 μg/mL) inhibits Notch1 signaling, including DLL4, JAG1/2 activity.Brontictuzumab (25 μg/mL, 4 days) reduces the levels of Notch1 intracellular domain in the HPB-ALL cell line.Brontictuzumab (25 μg/mL, 48 h) inhibits DLL4-mediated cleaved-Notch1 overexpression in MCL cells.Brontictuzumab (25 μg/mL, 48 h) blocks the increased phosphorylation of both, MEK and ERK by DLL4 stimulation in Mino cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备